ロバート・ガーバー：ヘルスケアイノベーションとヘルステック投資の未来

Healthcare is the largest industry on earth. Global health expenditure exceeds $9 trillion annually — roughly 10% of world GDP. And yet, by almost every efficiency measure, it remains one of the least digitized, least data-driven, and least consumer-oriented sectors in the modern economy. Administrative waste alone consumes an estimated $1 trillion per year in the United States. In Japan, a physician shortage projected to reach 30,000 by 2030 collides with the fastest-aging population in human history. Across both countries and globally, the gap between what healthcare costs and what it delivers continues to widen.

This is the gap that health technology investors are racing to close. And few firms have approached that race with more precision than 7wire Ventures, the Chicago-based venture capital firm that has built its thesis around a single conviction: the future of healthcare belongs to the empowered consumer.

Robert Garber, who brings 7wire Ventures’ perspective to the Tech for Impact Summit 2026 in Tokyo on April 26, represents an investment philosophy that sits at the intersection of technology, healthcare, and the belief that patients — not institutions — should be at the center of the system.

The 7wire Thesis: Connected Health Consumers

7wire Ventures was founded on a thesis that remains as relevant today as when the firm launched: healthcare is migrating from a provider-driven model to a consumer-driven one, and the companies that enable that migration will capture disproportionate value.

This is not a generic bet on “health tech.” It is a specific investment framework organized around what the firm calls the Connected Health Consumer — the patient who uses data, digital tools, and personalized services to manage their own health journey. The firm’s portfolio reflects this focus: companies building infrastructure for virtual care delivery, health data interoperability, personalized wellness, behavioral health platforms, and the digital front doors through which patients increasingly enter the healthcare system.

The thesis is rooted in a structural observation. In nearly every other industry — finance, retail, travel, media — technology has shifted power from institutions to individuals. Healthcare is the last great holdout. The regulations are complex, the incumbents are massive, the data is fragmented, and the stakes of failure are measured in human lives rather than quarterly earnings. But the forces driving consumer empowerment elsewhere — mobile access, data portability, AI-powered personalization — are now reaching healthcare with compounding force.

7wire’s track record suggests the thesis is working. The firm’s portfolio companies operate across the health tech stack, from patient engagement and clinical decision support to data infrastructure and health plan administration. Their approach combines healthcare domain expertise with technology investing discipline — a combination that is surprisingly rare in a sector where generalist tech investors often underestimate regulatory complexity and healthcare-native investors often underestimate technology’s rate of change.

Digital Health in 2026: Beyond the Pandemic Bump

The COVID-19 pandemic accelerated telehealth adoption by an estimated decade in 12 months. Virtual care visits in the United States surged from roughly 1% of ambulatory visits in February 2020 to over 40% by April 2020. The question that has defined the sector since is: how much of that adoption is permanent?

The answer, five years on, is more nuanced than either the bulls or bears predicted. Telehealth has not replaced in-person care, nor has it retreated to pre-pandemic levels. It has settled into a hybrid model where virtual care handles an expanding share of primary care consultations, mental health services, chronic disease management, and post-surgical follow-ups. McKinsey estimates that approximately 20% of all healthcare spending — across all categories — could eventually be delivered virtually.

But the more consequential shift is happening underneath the telehealth headline. The real transformation is not about video calls replacing office visits. It is about the data infrastructure being built to support continuous, personalized, proactive health management. Remote patient monitoring devices, wearable sensors, AI-powered symptom checkers, and predictive analytics engines are creating a layer of health intelligence that did not exist a decade ago.

Consider the trajectory of AI in clinical diagnostics. In 2024, the FDA had cleared over 900 AI-enabled medical devices — up from fewer than 100 in 2019. These are not experimental curiosities. They include AI systems that detect diabetic retinopathy from retinal scans with accuracy matching or exceeding human ophthalmologists, algorithms that identify early signs of sepsis from electronic health records hours before clinicians would, and imaging analysis tools that flag potential cancers in mammograms and CT scans. The radiology department of 2026 looks fundamentally different from 2020 — not because radiologists have been replaced, but because they now have AI co-pilots that process information at speeds and scales that human cognition cannot match.

For health tech investors, the shift from “pandemic-driven adoption” to “AI-driven infrastructure” represents a maturation of the sector. The companies that succeed in this phase will not be the ones that simply digitize existing workflows. They will be the ones that use technology to change what healthcare fundamentally is: from a system that treats disease after it occurs to one that predicts, prevents, and personalizes care before symptoms appear.

Japan: The World’s Most Important Health Tech Market

If you want to understand the future of healthcare — not just for one country, but for the world — look at Japan.

Japan’s demographic profile is not a warning. It is a preview. With 29.3% of its population over age 65 — the highest proportion of any major economy — Japan is already living the reality that Germany, South Korea, China, and eventually the United States will face in the coming decades. The country’s healthcare system spends approximately $550 billion annually, the third highest globally in absolute terms, and that figure is rising as the population ages and chronic disease prevalence increases.

The pressure this creates is immense. Japan faces a projected shortage of 30,000 physicians by 2030 and an even more acute shortage of nurses and caregivers. The ratio of working-age adults to elderly dependents has fallen below 2:1 and continues to decline. The current model — in which healthcare is delivered primarily through in-person consultations at hospitals and clinics, supported by a dense network of pharmacies — is approaching its structural limits.

This is precisely why Japan may become the most consequential market for health technology deployment. When a system faces existential pressure, it innovates — not because it wants to, but because it must.

Japan’s government has signaled its recognition of this imperative. The Digital Agency, established in 2021, has made healthcare digitization a core priority, including the nationwide rollout of the My Number Card system as a digital health insurance card. The Ministry of Health, Labour and Welfare has expanded telemedicine regulations, relaxing restrictions on initial consultations conducted virtually and enabling online prescription services. Japan’s pharmaceutical industry — the third largest globally — is investing heavily in digital therapeutics, AI-powered drug discovery, and precision medicine.

The opportunity for international health tech companies is significant and under-explored. Japan’s healthcare market combines high spending, sophisticated consumers, strong IP protections, and a government actively seeking technology solutions to demographic challenges. The barriers — language, regulatory navigation, business culture — are real but surmountable, particularly for companies with partners who understand both the technology and the market.

The Convergence: AI, Longevity, and Impact

The health tech investment thesis intersects with several of the core themes of the Tech for Impact Summit 2026: the role of AI in reshaping established industries, the economic implications of demographic change, and the question of whether technology can deliver equitable outcomes rather than merely efficient ones.

The longevity economy — the economic ecosystem serving people over 50 — is already worth an estimated $22 trillion globally. As populations age across the developed world and increasingly in emerging economies, the companies that build infrastructure for healthy aging will capture extraordinary value. But the social impact question is equally pressing: will advanced health technology be available only to those who can afford concierge medicine and cutting-edge diagnostics? Or can it be deployed at population scale, reducing disparities rather than widening them?

Japan offers a compelling case study in both directions. Its universal health insurance system ensures broad access to care. Its embrace of technology adoption among elderly populations — Japan leads the world in acceptance of assistive robotics and health monitoring devices — suggests that technology-enabled care can work for aging societies. At the same time, the rural-urban divide in healthcare access is widening, specialist wait times are growing, and the system is straining under costs that show no sign of plateauing.

The investors and builders who can navigate this complexity — delivering technology that is clinically effective, economically viable, and accessible at scale — will define the next era of healthcare. That is a challenge worth bringing to a room full of leaders who think in decades, not quarters.

What Robert Garber Will Discuss at T4IS 2026

At the Tech for Impact Summit, Garber will bring the health tech investing perspective to a conversation that spans technology, capital, and social impact. His contribution will address how venture capital can be deployed to accelerate healthcare innovation that serves populations, not just portfolios — and why Japan’s demographic urgency makes it a proving ground whose lessons will apply globally.

He joins a speaker lineup that approaches impact from multiple vectors. Former Minister Taro Kono brings the policy architecture of Japan’s digital transformation, including healthcare digitization. Yoshito Hori, founder and president of GLOBIS, delivers the keynote on leadership and human capital. Kathy Matsui of MPower Partners speaks to impact-driven venture capital. Charles Hoskinson, founder of Cardano, addresses the decentralized infrastructure that could underpin new models of health data ownership and portability. Jesper Koll of Monex Group provides the macroeconomic context for Japan’s structural transformation.

The summit’s invitation-only format — an intimate gathering of senior executives, policymakers, and technologists at Tokyo Garden Terrace Kioi Conference — is designed for the kind of cross-sector conversation that healthcare transformation demands. The solutions to aging societies, physician shortages, and health equity gaps will not come from any single industry. They will come from the convergence of technology, capital, policy, and purpose.

That convergence is what Tech for Impact Summit 2026 is built to catalyze.

---

The Tech for Impact Summit 2026 takes place on April 26 in Tokyo. To learn more about partnership opportunities, visit tech4impactsummit.com.

Watch the highlight video from previous editions: youtu.be/ujy7ZXflrt4